Pricing Log in Create free account

bioAffinity Technologies, Inc. (BIAF) vs XWELL, Inc. (XWEL)

bioAffinity Technologies, Inc. and XWELL, Inc. are both Diagnostics & Research companies. XWELL, Inc. is the larger, with a market value of $6.1M against $3.3M — 1.8× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −23.2%. XWELL, Inc. has the higher net margin (−117.8% vs −257.3%) and the higher return on invested capital (0.00% vs −408.7%). Across the 18 metrics below, XWELL, Inc. leads on 12 and bioAffinity Technologies, Inc. on 6.

Valuation

Metric BIAF XWEL Diagnostics & Research median
P/E n/m n/m 34.52
P/S 0.16 0.17 4.24
P/B 0.25 0.59 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA 0.08 0.12 23.44
EV/Sales (0.16) (0.06) 5.18
Earnings yield (3,812.50%) (933.33%) (1.50%)
Free cash flow yield (1,223.67%) (278.57%) 0.00%

Profitability

Metric BIAF XWEL Diagnostics & Research median
Gross margin 34.61% 34.34% 48.32%
Operating margin (209.82%) (61.31%) (5.68%)
Net margin (257.33%) (117.83%) (4.10%)
Free cash flow margin (195.90%) (47.65%) 0.00%
Return on equity (1,860.15%) (557.21%) 0.00%
Return on assets (245.51%) (155.10%) (6.05%)
Return on invested capital (408.67%) 0.00% 0.00%

Growth

Metric BIAF XWEL Diagnostics & Research median
Revenue growth (TTM) (23.18%) (7.58%) 8.99%
EPS growth (last fiscal year) 61.55% (38.80%) 20.36%
Revenue growth, 5-year CAGR — 28.35% 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF XWEL Diagnostics & Research median
Debt to equity 0.15 0.00 0.01
Current ratio 1.44 2.27 2.27
Net debt to EBITDA 0.57 (0.08) 0.68

Dividend

Metric BIAF XWEL Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric BIAF XWEL Diagnostics & Research median
Market cap 3.34m 6.08m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack